The development of new antibiotics to treat superbugs and other bacterial infections is a global priority, with the rate of infections that cannot be treated with current antibiotics rising and ...

An international research group led by the Helmholtz Center for Infection Research (HZI) has discovered a promising new drug ...

Drug-resistant infections—especially from deadly bacteria like tuberculosis and staph—are a growing global health crisis.

Pneumonia caused by the bacterium Staphylococcus aureus is one of the most dangerous infections that can occur in hospital.

Known for spending much of its life underground, the little-known American burying beetle could hold the key to developing ...

The US accounts for 80% to 90% of the total market for anti-MRSA antibiotics, so FDA approval is key to growing ceftobiprole's revenues, currently a minor part of its CHF 131 million ($137 million ...

Other antibiotics bind to proteins that can easily change through mutations, Lewis adds. Teixobactin has thus been effective in treating staph MRSA infections and strep pneumonia in animal models.